Overview

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the effect of IV iron isomaltoside 1000 compared with placebo on Hb in first-time female donors with p-ferritin below 30 µg/L
Phase:
Phase 3
Details
Lead Sponsor:
Pharmacosmos A/S
Collaborator:
Max Neeman
Treatments:
Ferric Compounds
Iron
Iron isomaltoside 1000